Research method
Immunofluorescence Staining
Immunofluorescence uses antibodies (or fluorescent tags) to mark a protein, organelle, or pathogen antigen in fixed or live cells, then images where the signal sits. The output is a localisation pattern — surface versus endosome, apical pole, tissue-resident T cells — sometimes scored as a binary infected/uninfected well. Antibody cross-reactivity and fixation artifacts are part of the uncertainty.
Host–pathogen and trafficking papers reach for IF when they need to see a receptor, a viral protein, or a polarity marker in place rather than only on a blot. It answers 'where is this epitope, and does a mutation or drug move it?' Its main limitation is that staining intensity is not a binding affinity, and a Vero-cell antiviral screen or a permeabilized-sperm assay does not automatically generalise to human tissue.
Evidence
What the evidence shows
Drawn from 8 studies in this library. Each finding starts with a plain-language takeaway, then the denser detail. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope with a short note on each study’s contribution. Challenged positions are labeled — they are not findings.
Permeabilized sperm plus staged inhibitors and photolabile Ca2+ chelators ordered acrosome exocytosis: Rab3A acts before intra-acrosomal Ca2+ efflux; SNAREs and synaptotagmin act after to complete fusion. Immunofluorescence of fusion factors here is timed biochemistry in a stripped-down cell, not every in-vivo regulatory layer.
A Vero E6 SARS-CoV-2 assay screened about 430 kinase inhibitors: the ATR inhibitor berzosertib showed strong antiviral activity, and 100 nM fully blocked replication at 48 hours post-infection in that assay. Infection staining or antigen IF is a screening endpoint, not a completed human COVID-19 efficacy trial.
USP8 is required for Hedgehog-induced Smoothened surface accumulation and keeps Smo out of Rab5 early endosomes. Site-specific monoubiquitination of Rab5 at K140 and K165 (not K116) downregulates the endocytic pathway via disrupted effectors and nucleotide conversion. Both papers use localisation of Smo or Rab5 as a trafficking IF readout.
Study Role Design N Population Outcome How does USP8 turn on Smoothened? Supports Animal / in-vitroRNAi screen of Drosophila DUBs in wings and S2 cells focused on USP8–Smo regulation Drosophila genetics and S2 cell assays — no single sample N Drosophila tissues and S2 cells USP8 prevention of Smoothened ubiquitination promoting Hedgehog signaling How does monoubiquitin turn down Rab5? Supports Animal / in-vitroMapped Rab5 monoubiquitination sites and tested chemically monoubiquitinated Rab5 function Cell-biochemistry of Rab5 ubiquitin sites K116/K140/K165 — no single sample N Cultured cells expressing Rab5 variants Site-specific monoubiquitination downregulating Rab5 endocytic signaling In resected human TB lung from 35 patients, PD-1 marked tissue-resident T cells; infection models then showed that TNF-α is primarily responsible for anti-PD-1–driven reactivation and that TNF neutralization reverses the phenotype. Tissue IF here is a human spatial observation paired with mechanistic models, not a randomized oncology endpoint trial.
Enteroid polarity reversed within hours without BME, with β1 integrin orienting apical pathogen access. Spike LYQD mutants altered S2 glycosylation mobility, and palmitoylation at cysteine clusters I/II was required for Golgi/plasma-membrane targeting and ACE2-mediated fusion. Those localisation phenotypes are IF/trafficking stains; enteroids are not a clinical gut, and much spike work uses pseudoviruses.
Study Role Design N Population Outcome Apical-out enteroids for pathogen access Supports Animal / in-vitroHuman enteroids cultured in suspension without BME to reverse polarity for apical pathogen assays Enteroid lines from multiple donors; assays often scored ~10 enteroids per well across experiments — no single primary N Human intestinal enteroids β1-integrin–dependent epithelial polarity orientation for host–pathogen assays Spike glycosylation and palmitoylation trafficking Supports Animal / in-vitroMutagenesis and 2BP inhibition of SARS-CoV-2 spike glycosylation/palmitoylation trafficking Cell-based spike trafficking/fusion assays — no single primary analytic N Cells expressing wild-type or mutant SARS-CoV-2 spike Spike intracellular trafficking, packaging, and ACE2-mediated fusion
Open questions
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes — limits on how far one study travels — not a forced fight between papers.
IF is a screening camera in Vero cells (berzosertib 100 nM, 48 hpi), a tissue census in TB lung (35 patients), a trafficking assay for Smo/Rab5/spike, and a polarity assay in enteroids. 'Positive staining' in a drug screen is not the same claim as PD-1 on human tissue-resident T cells or as K140/K165 moving Rab5 off endosomes.
- ATR inhibitor blocks SARS-CoV-2
- PD-1 blockade reactivates TB via TNF
- How does monoubiquitin turn down Rab5?
- Apical-out enteroids for pathogen access
Study Role Design N Population Outcome ATR inhibitor blocks SARS-CoV-2 Supports Animal / in-vitroMedium-throughput SARS-CoV-2 antiviral screen of kinase inhibitors in Vero E6 cells ~430 kinase inhibitors screened; cell-assay study without a human sample N Vero E6 cells infected with SARS-CoV-2 Antiviral activity of kinase inhibitors (notably berzosertib/ATR) PD-1 blockade reactivates TB via TNF Supports OtherHuman TB lung PD-1+ T-cell profiling plus infection models of anti-PD-1 effects N=35 · 35 patients with medically indicated lung resection; matched blood for 23; animal/in-vitro models secondary Patients undergoing lung resection for TB or sequelae (plus infection models) PD-1 expression and TNF-dependent effects of PD-1 blockade in TB How does monoubiquitin turn down Rab5? Supports Animal / in-vitroMapped Rab5 monoubiquitination sites and tested chemically monoubiquitinated Rab5 function Cell-biochemistry of Rab5 ubiquitin sites K116/K140/K165 — no single sample N Cultured cells expressing Rab5 variants Site-specific monoubiquitination downregulating Rab5 endocytic signaling Apical-out enteroids for pathogen access Supports Animal / in-vitroHuman enteroids cultured in suspension without BME to reverse polarity for apical pathogen assays Enteroid lines from multiple donors; assays often scored ~10 enteroids per well across experiments — no single primary N Human intestinal enteroids β1-integrin–dependent epithelial polarity orientation for host–pathogen assays Permeabilized-sperm SNARE timing and live epithelial polarity/spike trafficking disagree about how much native membrane regulation is still present. In-vitro sperm may miss in-vivo layers; enteroids and pseudovirus spike assays only approximate infection of a human airway or gut.
- SNARE timing in sperm acrosome exocytosis
- Apical-out enteroids for pathogen access
- Spike glycosylation and palmitoylation trafficking
Study Role Design N Population Outcome SNARE timing in sperm acrosome exocytosis Supports Animal / in-vitroStaged inhibitors and photolabile Ca²⁺ chelators in permeabilized sperm to order fusion factors Cell-biology ordering experiments — no single primary analytic N in stored text Permeabilized sperm undergoing acrosomal exocytosis Temporal order of Rab3A and SNARE/synaptotagmin steps in acrosomal fusion Apical-out enteroids for pathogen access Supports Animal / in-vitroHuman enteroids cultured in suspension without BME to reverse polarity for apical pathogen assays Enteroid lines from multiple donors; assays often scored ~10 enteroids per well across experiments — no single primary N Human intestinal enteroids β1-integrin–dependent epithelial polarity orientation for host–pathogen assays Spike glycosylation and palmitoylation trafficking Supports Animal / in-vitroMutagenesis and 2BP inhibition of SARS-CoV-2 spike glycosylation/palmitoylation trafficking Cell-based spike trafficking/fusion assays — no single primary analytic N Cells expressing wild-type or mutant SARS-CoV-2 spike Spike intracellular trafficking, packaging, and ACE2-mediated fusion
Common misconceptions
If 100 nM berzosertib fully blocks SARS-CoV-2 staining in Vero cells at 48 hpi, it is a proven COVID-19 drug.
That figure is a kinase-inhibitor screen endpoint in Vero E6 cells (~430 compounds). It is not a completed human clinical efficacy trial.
Any ubiquitin on Rab5 shuts the endocytic pathway down.
Rab5 is monoubiquitinated at K116, K140 and K165; K140/K165 modifications downregulate the pathway while K116 has little localisation effect. Site matters.
PD-1 staining on TB-lung T cells means anti-PD-1 cancer therapy always reactivates tuberculosis by a T-cell–intrinsic switch independent of TNF.
PD-1 is present on tissue-resident T cells in 35 patients' resected lung, but infection models found TNF-α primarily responsible and neutralization reversed the anti-PD-1 phenotype.
Exam-style questions
Short-answer questions that ask you to explain or compare, not recall.
Rab3A acts before intra-acrosomal Ca2+ efflux, SNAREs after. What did immunofluorescence plus staged inhibitors allow that a single endpoint stain would miss?
Order. Photolabile chelators and inhibitors placed Rab3A upstream of Ca2+ efflux and SNAREs/synaptotagmin at fusion completion. A single stained snapshot cannot sequence those steps.
A colleague treats berzosertib's 100 nM full block at 48 hpi as equivalent to PD-1 IF in 35 TB lungs. How do the IF claims differ?
Berzosertib is a Vero-cell antiviral screen with low-toxicity filters, not a human trial. TB-lung IF shows PD-1 on tissue-resident T cells in patients, then models implicate TNF. One is a drug-hit image; the other is human tissue localisation plus mechanism.
Why does monoubiquitination at Rab5 K116 versus K140/K165 change what an IF localisation experiment can conclude?
K140/K165 disrupt effectors and nucleotide conversion and downregulate endocytic localisation; K116 has little localisation effect. A pan-ubiquitin stain without site mutants would blur those outcomes.
Spike palmitoylation at cysteine clusters I/II is required for Golgi/plasma-membrane targeting. What IF pattern would you expect if 2-bromopalmitate blocks that step, and what caveat remains?
Less efficient surface/Golgi targeting of S and weaker ACE2-mediated fusion. Much of the work uses spike pseudoviruses rather than full-virus genetics for every assay, so the IF pattern is a trafficking phenotype, not a clinical antiviral result.
The studies
8 studies in this library bear on Immunofluorescence Staining, ordered by citations.
- Apical-out enteroids for pathogen access
Suspending human enteroids without ECM flips polarity so microbes can meet the apical face.
- What marks definitive endoderm progenitors in hESCs?
Single-cell RNA-seq separates definitive endoderm progenitors and links metabolism/hypoxia to DE differentiation.
- How does USP8 turn on Smoothened?
USP8 deubiquitinates Smoothened, promoting Hh-dependent cell-surface accumulation and signaling while limiting early-endosome localization.
- ATR inhibitor blocks SARS-CoV-2
DDR/ATR inhibitor berzosertib potently blocks SARS-CoV-2 replication in cell culture.
- PD-1 blockade reactivates TB via TNF
Anti-PD-1 immunotherapy can reactivate tuberculosis through TNF-α dysregulation.
- SNARE timing in sperm acrosome exocytosis
Sperm acrosome exocytosis proceeds via ordered SNARE assembly/disassembly around intra-acrosomal Ca2+ release.
- How does monoubiquitin turn down Rab5?
Rab5 is monoubiquitinated at specific lysines; ubiquitin at K140/K165 disrupts effector binding and downregulates endocytic trafficking.
- Spike glycosylation and palmitoylation trafficking
Glycosylation motifs and cysteine palmitoylation steer SARS-CoV-2 spike maturation, Golgi trafficking, and fusion.
Learn alongside